Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/04/23 Free

Executive/Senior Manager

4,00,000 0.6684%
01/02/23 Free

Chief Technology Officer

4,00,000 0.6686%
01/02/23 Free

Chief Operating Officer

4,00,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 29.5L
-0.70%+24.68%+76.72%+103.05% 7.09TCr
-2.35%+2.88%+35.39%+64.72% 5.54TCr
-0.88%+35.91%+18.89%+498.35% 2.94TCr
-0.30%+18.51%+56.61%+4.86% 2.41TCr
-0.47%+0.90%-15.64%-13.80% 2.33TCr
+0.05%+6.12%+46.81%-21.81% 1.84TCr
+9.77%+25.32%+252.40%+442.16% 1.7TCr
0.00%+10.84%+31.14%+628.97% 1.61TCr
-2.20%-7.58%+38.35%+140.50% 1.31TCr
Average -1.05%+390.71%+60.07%+205.22% 2.97TCr
Weighted average by Cap. -0.33%+349.16%+56.43%+165.97%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock